FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123873764> ?p ?o ?g. }

• W3123873764 endingPage "387" @default.
• W3123873764 startingPage "377" @default.
• W3123873764 abstract "ObjectivesTo evaluate the cost-effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) from a payer perspective in the United States.MethodsA partitioned survival model was developed to assess the cost-effectiveness of cemiplimab versus historical standard of care (SOC). All inputs were identified based on a systematic literature review, supplemented by expert opinion where necessary. Clinical inputs for cemiplimab were based on individual patient data from a cemiplimab phase 2 single-arm trial (NCT27060498). For SOC, analysis was based on a pooled analysis of single-arm clinical trials and retrospective studies evaluating chemotherapy and epidermal growth factor receptor inhibitors (cetuximab, erlotinib, and gefitinib) identified via a systematic literature review (6 of the 27 included studies). Overall survival and progression-free survival were extrapolated over a lifetime horizon. Costs were included for drug acquisition, drug administration, management of adverse events, subsequent therapy, disease management, and terminal care. Unit costs were based on published 2019 US list prices.ResultsIn the base case, cemiplimab versus SOC resulted in an incremental cost-effectiveness ratio of $99 447 per quality adjusted-life year (QALY), where incremental costs and QALYs were $372 108 and 3.74, respectively. At a willingness-to-pay threshold of $150 000/QALY, the probabilistic sensitivity analysis suggests a 90% probability that cemiplimab is cost-effective compared to SOC. Scenario analyses resulted in incremental cost-effectiveness ratios ranging from $90 590 to $148 738.ConclusionsCompared with historical SOC, cemiplimab is a cost-effective use of US payer resources for the treatment of advanced CSCC and is expected to provide value for money." @default.
• W3123873764 created "2021-02-01" @default.
• W3123873764 creator A5016395117 @default.
• W3123873764 creator A5016531633 @default.
• W3123873764 creator A5023676876 @default.
• W3123873764 creator A5031295196 @default.
• W3123873764 creator A5043968037 @default.
• W3123873764 creator A5051493673 @default.
• W3123873764 creator A5053262468 @default.
• W3123873764 creator A5054395916 @default.
• W3123873764 creator A5055398648 @default.
• W3123873764 creator A5058902095 @default.
• W3123873764 creator A5062209557 @default.
• W3123873764 creator A5064500437 @default.
• W3123873764 date "2021-03-01" @default.
• W3123873764 modified "2023-10-16" @default.
• W3123873764 title "Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis" @default.
• W3123873764 cites W1980709802 @default.
• W3123873764 cites W1987604182 @default.
• W3123873764 cites W1987768576 @default.
• W3123873764 cites W2015368967 @default.
• W3123873764 cites W2017628547 @default.
• W3123873764 cites W2040600853 @default.
• W3123873764 cites W2046169609 @default.
• W3123873764 cites W2058056848 @default.
• W3123873764 cites W2059573268 @default.
• W3123873764 cites W2096552494 @default.
• W3123873764 cites W2101027485 @default.
• W3123873764 cites W2101157733 @default.
• W3123873764 cites W2112875965 @default.
• W3123873764 cites W2119358637 @default.
• W3123873764 cites W2126634195 @default.
• W3123873764 cites W2128473443 @default.
• W3123873764 cites W2134047636 @default.
• W3123873764 cites W2138729791 @default.
• W3123873764 cites W2152061559 @default.
• W3123873764 cites W2155752258 @default.
• W3123873764 cites W2157466346 @default.
• W3123873764 cites W2163076565 @default.
• W3123873764 cites W2264465777 @default.
• W3123873764 cites W2316377680 @default.
• W3123873764 cites W2380316500 @default.
• W3123873764 cites W2593914131 @default.
• W3123873764 cites W2625652544 @default.
• W3123873764 cites W2650689221 @default.
• W3123873764 cites W2747016053 @default.
• W3123873764 cites W2759377993 @default.
• W3123873764 cites W2792512660 @default.
• W3123873764 cites W2801300331 @default.
• W3123873764 cites W2802689544 @default.
• W3123873764 cites W2802935287 @default.
• W3123873764 cites W2805968856 @default.
• W3123873764 cites W2891215954 @default.
• W3123873764 cites W2898122739 @default.
• W3123873764 cites W2908902360 @default.
• W3123873764 cites W2916864756 @default.
• W3123873764 cites W2947552510 @default.
• W3123873764 cites W2947556250 @default.
• W3123873764 cites W2971382867 @default.
• W3123873764 cites W3000739799 @default.
• W3123873764 doi "https://doi.org/10.1016/j.jval.2020.09.014" @default.
• W3123873764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33641772" @default.
• W3123873764 hasPublicationYear "2021" @default.
• W3123873764 type Work @default.
• W3123873764 sameAs 3123873764 @default.
• W3123873764 citedByCount "15" @default.
• W3123873764 countsByYear W31238737642021 @default.
• W3123873764 countsByYear W31238737642022 @default.
• W3123873764 countsByYear W31238737642023 @default.
• W3123873764 crossrefType "journal-article" @default.
• W3123873764 hasAuthorship W3123873764A5016395117 @default.
• W3123873764 hasAuthorship W3123873764A5016531633 @default.
• W3123873764 hasAuthorship W3123873764A5023676876 @default.
• W3123873764 hasAuthorship W3123873764A5031295196 @default.
• W3123873764 hasAuthorship W3123873764A5043968037 @default.
• W3123873764 hasAuthorship W3123873764A5051493673 @default.
• W3123873764 hasAuthorship W3123873764A5053262468 @default.
• W3123873764 hasAuthorship W3123873764A5054395916 @default.
• W3123873764 hasAuthorship W3123873764A5055398648 @default.
• W3123873764 hasAuthorship W3123873764A5058902095 @default.
• W3123873764 hasAuthorship W3123873764A5062209557 @default.
• W3123873764 hasAuthorship W3123873764A5064500437 @default.
• W3123873764 hasBestOaLocation W31238737641 @default.
• W3123873764 hasConcept C112930515 @default.
• W3123873764 hasConcept C121608353 @default.
• W3123873764 hasConcept C126322002 @default.
• W3123873764 hasConcept C143998085 @default.
• W3123873764 hasConcept C2779438470 @default.
• W3123873764 hasConcept C2780580887 @default.
• W3123873764 hasConcept C3019080777 @default.
• W3123873764 hasConcept C515549039 @default.
• W3123873764 hasConcept C535046627 @default.
• W3123873764 hasConcept C71924100 @default.
• W3123873764 hasConceptScore W3123873764C112930515 @default.
• W3123873764 hasConceptScore W3123873764C121608353 @default.
• W3123873764 hasConceptScore W3123873764C126322002 @default.
• W3123873764 hasConceptScore W3123873764C143998085 @default.
• W3123873764 hasConceptScore W3123873764C2779438470 @default.

• next